Tagged with Switzerland

Pharma Janssen Switzerland’s Ludo Ooms highlights the strengths of the Swiss healthcare and life sciences sector including the efficiency of the government, a productive and well trained workforce, the national pricing system, and the climate for innovation; all factors which make Switzerland a strategic market for Johnson & Johnson and Janssen.…

Pharma Professor Dr. Susan M. Gasser of the Friedrich Miescher Institute for Biomedical Research describes FMI’s fundamental connection between academia and industry in Switzerland, the effects of the foundation’s research, notably on Novartis, and future projects in the making. Could you begin by introducing both yourself and your institute to our…

Pharma Pfizer Switzerland’s Pamela Alexa discusses launching Xeljanz (tofacitinib), a treatment for adult patients with moderate to severe active rheumatoid arthritis, building upon Pfizer’s tradition of developing patient-centered therapies. She also discusses supporting research in Switzerland through the Pfizer Research Prize Foundation, which celebrates its 25th anniversary in 2016. What have…

Pharma Switzerland’s pharma industry is moving beyond staid conservatism and embracing risk in order to compete internationally and foster a new culture of innovation. Switzerland is frequently considered one of the most entrepreneurial and competitive countries in the world. As Thomas Cunei, secretary general of Interpharma, the association that represents 92…

Health In the year of Gen Suisse’s 25th anniversary, CEO Daniela Suter talks supporting dialogue between scientists and politicians on life sciences in Switzerland, educating the general population, the attractiveness of the Swiss community for scientists, and her goals for the future. Could you give our international viewers an overview of…

R&D Professor Dr. Robert Riener speaks about the much anticipated Cybathlon event and its importance to technology transfer, the Swiss education system’s ability to attract international talent, and his goals for the future. You have been leading the Department of Health Sciences and Technology at ETH Zurich since February 2016. Could…

Pharma Martin Naville, CEO of the Swiss-American Chamber of Commerce, discusses Swiss exports to the US, global competitiveness and innovation rankings, and why the Swiss-US relationship will only continue to grow stronger in the coming years. In 2015, the US was the most important destination for Swiss direct investment abroad, amounting…

Pharma Axel B. Müller, managing director of Intergenerika, the Swiss generics association, reveals the penetration rate of generics in Switzerland; why generics are a safe, and smarter choice, manufactured to modern standards with affordable prices; and the threat of government forcing generic companies to benchmark their prices to nine European countries…

Pharma Alessandra Modenese Kauffmann, General Manager of the Swiss Chamber of Commerce, shares her insights into the relationship between Italy and Switzerland, the Chamber’s efforts to foster trade between the two countries and the opportunities offered through close collaboration between Swiss and Italian companies. Alessandra, the chamber has been active in…